Orion Pharma Limited announcements
187 Dhaka Stock Exchange announcements for Orion Pharma Limited (ORIONPHARM) since 2013: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2024 (19).
- Credit Rating Result
Credit Rating Agency of Bangladesh Limited (CRAB) has announced the surveillance rating of the Company as "AA3" in the long term and "ST-3" in the short term along with Stable outlook based on audited financial statements (FYE 30/06/ 2024, 30/06/2023, 30/06/2022), bank liability position as on 30/11/ 2024 and other information up to the date of rating declaration.
- Resumption after Record date
Trading of the shares of the company will resume on 05.12.2024.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 04.12.2024.
- Spot for AGM and EGM
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 02.12.2024 to 03.12.2024 and trading of the shares will remain suspended on record date i.e., 04.12.2024 for AGM and EGM.
- Emphasis of Matter and Other Matter
The auditor of the company has given the "Emphasis of Matter" and "Other Matter" paragraphs in the Auditor's Report of the company for the year ended June 30, 2024. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2024/November/ORIONPHARMA_2024.pdf
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 0.24 for July-September 2024 as against Tk. 0.76 for July-September 2023; Consolidated NOCFPS was Tk. 1.85 for July-September 2024 as against Tk. 3.89 for July-September 2023. Consolidated NAV per share was Tk. 89.88 (including revaluation surplus) as on September 30, 2024 and Tk. 92.05 as on June 30, 2024. Consolidated NAV per share was Tk. 82.11 (excluding revaluation surplus) as on September 30, 2024 and Tk. 84.27 as on June 30, 2024. (cont.) (Cont. news of ORIONPHARM): Reasons for deviation: Consolidated EPS has decreased due to decrease in sales as well as power supply of subsidiaries during the period from the previous period. NOCFPS decreased due to decrease in cash received from customer than the previous corresponding period. (end)
- Dividend Declaration and EGM for Related Party Transaction
The Board of Directors has recommended 10% cash dividend for the year ended June 30, 2024. The Board considered and recommended the proposal for approval of the shareholders regarding Related Party Transaction of the company for the Financial year ended June 30, 2024 and in this regard, the Board also advised to hold an EGM. Date of AGM and EGM: 26.12.2024, Time of AGM and EGM: 3:30 PM and 4:15 PM respectively, Venue: Digital Platform. Record Date for AGM and EGM: 04.12.2024. (cont.) (Continuation news of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 1.36, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 92.05, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 84.27 and Consolidated NOCFPS of Tk. 6.78 for the year ended June 30, 2024 as against Tk. 2.74, Tk. 88.99, Tk. 81.15 and Tk. 10.65 respectively for the year ended June 30, 2023. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (14.11.2024) following its corporate declaration.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2024 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2024 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
- Query Response
In response to the DSE query dated August 27, 2024, the company has informed that they do not have any undisclosed material decision/information relating to the company's operation/profitability that might have impact on price fall of shares of the company.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
- (Q3 Un-audited): Consolidated EPS was Tk. 0.42 for January-March 2024 as against Tk. 0.53 for January-March 2023; Consol
(Q3 Un-audited): Consolidated EPS was Tk. 0.42 for January-March 2024 as against Tk. 0.53 for January-March 2023; Consolidated EPS was Tk. 1.65 for July 2023-March 2024 as against Tk. 2.44 for July 2022-March 2023. Consolidated NOCFPS was Tk. 3.09 for July 2023-March 2024 as against Tk. 6.85 for July 2022-March 2023. (cont.)
- Q3 Financials
(Continuation news of ORIONPHARM): Consolidated NAV per share (excluding Revaluation Surplus) was Tk. 85.21 as on March 31, 2024 and Tk. 81.15 as on June 30, 2023. NAV per share (including Revaluation Surplus) was Tk. 93.01 as on March 31, 2024 and Tk. 88.99 as on June 30, 2023. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2024 at 03:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
- (Q2 Un-audited): Consolidated EPS was Tk. 0.47 for October-December 2023 as against Tk. 1.19 for October-December 2022;
(Q2 Un-audited): Consolidated EPS was Tk. 0.47 for October-December 2023 as against Tk. 1.19 for October-December 2022; Consolidated EPS was Tk. 1.23 for July-December 2023 as against Tk. 1.91 for July-December 2022. Consolidated NOCFPS was Tk. 2.68 for July-December 2023 as against Tk. 5.62 for July-December 2022. Consolidated NAV per share including revaluation surplus was Tk. 89.69 as on December 31, 2023 and Tk. 88.99 as on June 30, 2023. (cont.)
- Q2 Financials
(Continuation news of ORIONPHARM): Consolidated NAV per share excluding revaluation surplus was Tk. 81.87 as on December 31, 2023 and Tk. 81.15 as on June 30, 2023. (end).
The first part of this announcement is missing from the archive. - Q2 Financials (Additional Information)
The company has further informed that Consolidated EPS has been decreased due to decrease in revenue from previous period due to electricity supply is less than earlier. Consolidated NOCFPS has been decreased due to decrease in cash collection from previous period.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 31, 2024 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.